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Rational therapy requires ac-
curate diagnosis. When we apply 
this precept to anxiety a funda-
mental question arises. Is anxiety 
an illness in terms of the now be-
rated medical model which holds 
that an illness has a cause, a nat-
ural history, and hopefully a cure? 
Or is anxiety a basic aspect of the 
human condition, an innate pattern 
of response which becomes patho-
logical when stress, induced by 
physiologic and social forces, is 
magnified out of proportion to the 
original stimulus? If the latter is 
true, then stress and social inter-
actions are the causative factors, 
the anxiety only a reaction. Logi-
cally then, the condition of an-
xiety can be modified by alleviat-
ing stress or changing the social 
environment. Although there is no 
definitive answer to this major 
question concerning the nature of 
anxiety, we would like to present 
briefly some of the present knowl-
edge about it. 
In 1921, Freud stated: "We call 
it [anxiety] an affective state, al-
though we are also ignorant of 
what an affect is." He discussed 
three components of anxiety: (1) 
the specific feeling of unpleasure, 
(2) acts of discharge (autonomic 
and endocrine functions), and ( 3) 
perceptions of these acts. Although 
more knowledge of biochemical 
and neurophysiologic mechanisms 
has accumulated since Freud made 
this observation little more is 
known about anxiety. Engel 
( 1962) proposed that anxiety is 
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the earlier of two basic biological 
patterns of which depression-with-
drawal is second. He says that 
anxiety "includes a variety of ac-
tive modes of coping with stress 
which are designated the fiight-fight 
patterns to indicate corresponding 
behavioral aspects (Cannon, 1939). 
These involve not only the bio-
chemical and physiological prepara-
tions for flight or fight but also in-
ternal changes anticipating bodily 
injury." The psychophysiology of 
anxiety is neuroendocrinological, 
including activity of the limbic sys-
tem and the hypothalamus, which 
leads to activation of the pituitary-
adrenal cortical system and facili-
tates a wide range of metabolic 
processes involved in the long-term 
responses to injury (Engel, 1953; 
Ingle, 1952; Selye; 1960). 
Grinker (1956) characterized 
the clinical manifestations of an-
xiety quantitatively. Mild anxiety 
is consonant with alertness or vigi-
lance; it may be automatic, and the 
patient has little psychical or phys-
ical awareness of his anxiety. 
Greater quantities are manifested 
as episodes of recognized appre-
hension with physical symptoms. 
Thirdly, free anxiety, which may 
be episodic or continuous, is ob-
viously neurotic. As the anxiety 
becomes more severe, disorganiza-
tion of function occurs. 
These are the fundamental 
psychiatric concepts. For the sake 
of completeness we should include 
that Berger (1962) propounds a 
strictly organic point of view when 
he says that anxiety is a "disease 
of the brain." In contrast, others 
see anxiety as a patterned re-
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sponse; neurotic symptoms are 
learned faulty patterns of behavior 
(Hall and Lindzey, 1957). ' Fur-
ther, many theorists believe that 
anxiety is a constructive force, 
which not only acts as a danger 
signal to protect the organism, but 
also accounts for motivation and 
monitors behavior. 
In medicine, psychosomaticists 
hold that excessive or sustained 
anxiety produces disturbances of 
bodily functions or structures 
which in turn result in organic ill-
ness. Physicians find that anxiety is 
a contributing factor, a correlate, 
or a result of many disease states. 
They are concerned with treating 
patients with acute, distressing "an-
xiety" attacks and those with high 
levels of chronic anxiety who are 
difficult to work with because of 
their general nervousness, irrita-
bility, fright, and erratic behavior. 
Incidence of Anxiety 
Despite our difficulties in under-
standing the nature of anxiety, 
awareness of it is increasing in the 
Western world (Andresen, 1963; 
Finn and Rusten, 1966; Rennie, 
1948). Adams and Hope ( 1962) 
observe: "As a clinical syndrome, 
the anxiety state outranks all other 
problems in general medicine." 
Our studies (Schwab et al., 1966a, 
b, and c) with medical inpatients 
showed that 20% to 27 % of them 
had severe anxiety. These data are 
in accord with Cattell and Scheier's 
statement ( 1961 ) : "Epidemiologi-
cal estimates vary . . . [but] a con-
servative consensus estimate would 
probably place 20% of the Ameri-
can population as needing treat-
ment for disorders in which an-
xiety plays a prominent role." 
Treatment 
The effective treatment of an-
xious patients hinges on the com-
bined benefits of psychotherapy 
and medications. The limitations 
of psychotherapy are well known, 
and the limitations of drug therapy 
have been aptly expressed by 
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Goodman and Gilman ( 1965a) : 
"obviously neither drugs nor other 
somatic treatment can give the 
insight to the patient that can be 
achieved by psychotherapy." 
Psychotherapy 
We like Appel's definition of 
psychotherapy as quoted by Rick-
els (1964) : "helping people to 
handle their feelings, motivations, 
and behavior more appropriately." 
And we should remember that 
psychotherapy is one of the oldest 
medical skills. The essence of 
psychotherapy is communication, 
and achieving the therapeutic dia-
logue is dependent on the relation-
ship between the patient and the 
physician~ 
By listening, the therapist tries 
to obtain understanding, not neces-
sarily agreement but rather com-
prehension. Either sympathetic 
agreement or antagonistic disagree-
ment may produce distortions and 
solidify the neurotic organization. 
Thus, the task of the therapist is, 
in Wahl's words (1962) " ... to 
convert apprehension to compre-
hension." 
From awareness of his prob-
lems comes clarification; the pa-
tient is better able to make more 
appropriate decisions about his 
life. Other fundamentals of psycho-
therapy are the educative and the 
manipulative, deriving from in-
creased knowledge of self and en-
vironment. 
Just as communication is the 
essence of psychotherapy, self es-
teem is the fulcrum on which suc-
cess balances. Only with increased 
self esteem can the patient order 
his world and create healthful re-
lationships with it. 
Medication 
Medication is the second com-
ponent of treatment. When tran-
quilizers were first introduced, it 
was feared that they would render 
the patient too comfortahle for 
psychotherapy. Obviously, this fear 
has not been realized. Available 
medications do not purge anxiety, 
but they can reduce it to manage-
able proportions, thereby improv-
ing personal relationships, and 
forestalling ego disorganization 
and psychosis. 
Guidelines 
To obtain maximal advantages 
in the use of drugs, the therapist 
must adhere to certain principles. 
1. Little is known about their 
pharmacologic action. Most of 
these agents act as weak sedatives. 
The barbiturates, of course, are de-
pressants of the recticular forma-
tion in the brain stem. The action 
of meprobamate is quite similar; 
although no specific site of action 
has been identified. Hendley et al. 
(1954) indicated, however, that it 
produces some thalamic synchroni-
zation, and others have observed 
slow wave activity in the basal 
ganglia and limbic system. It may 
interfere with centrally mediated 
autonomic responses. Indirectly, by 
affecting cond~ction in the limbic 
system, it appears to depress the 
recticular formation. 
According to Goodman and 
Gilman (1965b), the effects of 
chlordiazepoxide (Librium) and 
the related compounds diazepam 
(Valium) and oxazepam (Serax) 
are more ubiquitous than those of 
meprobamate and the barbiturates. 
Chlordiazepoxide has a central ac-
tion, possible peripheral actions, 
and a definite sedative effect in-
termediate in potency between 
meprobamate and chlorpromazine. 
Like barbiturates and meproba-
mate, in experimental animals it 
blocks both conditioned and un-
conditioned avoidance responses. 
The phenothiazines (Thorazine, 
Mellaril, Stelazine) appear to pro-
duce changes at many levels: the 
EEG is characteristic of drowsi-
ness; arousal is diminished; there 
are some effects upon the limbic 
system and the basal ganglia; and 
conditioned avoidance responses 
are blocked without affecting the 
unconditioned responses. Jarvik 
( 1965) states that there are "sev-
eral disparate views concerning 
the sedative action of chlorproma-
zine and its effects on the recticu-
lar system." Various investigators 
contend that it depresses, that it 
has a biphasic action, or even that 
it is stimulating. Through its de-
pressive action on the hypothala-
mus, it has strong adrenergic and 
weak cholinergic blocking effects 
on the autonomic nervous system, 
and it acts on the endocrine sys-
tem to reduce urinary gonadotro-
pins, suppress estrous cycles, 
interfere with growth, induce lacta-
tion, and decrease secretion of 
ACTH. 
2. The dosage must be care-
fully individualized. For example, 
some patients respond to 1200 mg 
of meprobamate per day, whereas 
others receive little benefit unless 
that is doubled. This is even more 
true of the phenothiazines; some 
patients improve on 100 mg of 
chlorpromazine in 24 hours, 
whereas others require many times 
that amount. 
3. They provide only sympto-
matic relief by damping reactions 
and quieting inner turbulence. 
Thus they are only adjuncts. 
4. They are not remedies for 
psychosocial distress. Too often 
tranquilizers are prescribed for the 
treatment of sociocultural dilem-
mas; obviously when used for these 
purposes the results will be poor. 
5. Negative effects occur. Some 
patients react poorly to one or all 
of the antianxiety agents. Paradoxi-
cal reactions, to say nothing of 
side effects, are reported for me-
probamate, the benzodiazepine 
compounds (such as Librium), and 
the phenothiazines. 
6. Knowledge of the patient's 
personality is essential. DiMascio 
and Klerman ( 1960) concur with 
the almost universal recognition 
that the personality of the subject 
and his psychophysiologic state are 
important modifiers of drug action. 
Many anxious patients cannot tol-
erate a slowed-down feeling; it re-
sults in clinical depression for 
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some and a loss of required motor 
activity for others. Importantly, 
Rickels ( 1964) has described the 
effects of the barbiturates as pro-
ducing more improvement in lower 
socioeconomic patients who have 
low drive levels, low ambition, 
highly compliant behavior, and a 
strong passive-dependent character 
makeup. In the more intelligent, 
less dependent, less compliant and 
socioeconomically higher patient, 
the barbiturates are less well tol-
erated, producing more sedation 
and less improvement. 
7. The physician should restrict 
his use of the countless sedatives 
and tranquilizers available to only 
a few, so that he can become fa-
miliar with their indications, side 
effects, and contraindications. 
Sainz ( 1964) states : "The rate at 
which new psychopharmacologic 
agents appear and old ones disap-
pear attests only to their relative 
ineffectiveness." We advocate that 
one should switch to a new drug 
only when it has been proved 
demonstrably superior. Among the 
phenothiazines, chlorpromazine is 
still the standard against which 
others are measured. And, mepro-
bamate and chlordiazepoxide have 
been used for so many years with 
so many patients that their effects 
and side effects are well known. 
Clinical States 
In practice, patients are seen 
with various anxiety states, which 
can be conceptualized on two di-
mensions: the first is the con-
tinuum from conscious to uncon-
scious awareness of causes and 
dynamics; and the second is sever-
ity, ranging from the stress reac-
tion, which may be mild, to the 
extreme anxiety manifested by the 
schizophrenic patient who is under-
going ego disorganization. 
( 1) The acute stress reaction is 
evidenced clinically by: agitation, 
restlessness, autonomic symptoms, 
insomnia, and visceral dysfunc-
tions. Conscious elements are pre-
dominant; i.e., the patient is aware 
of his tension and is able to de-
scribe its causes and effects. The 
severity is commensurate with the 
degree of trouble the patient is en-
countering. The ordinary dilemmas 
of human existence, i.e., problems 
of work and family, are the most 
common causes. 
Psychotherapy should be di-
rected toward helping the patient 
resolve the environmental stress or 
removing him from it. Medications 
may be necessary, but in these in-
stances they should be given for 
only a short time because their 
chronic use may produce just 
enough relief that the patient, in-
stead of seeking resolution, re-
mains helplessly and symptomati-
cally caught in a stressful situation. 
Barbiturates, either sodium amytal 
or butabarbital (30 mg three or 
four times a day), are useful. 
Sometimes adequate sedation at 
bedtime suffices. Of course, bar-
biturates have drawbacks: seda-
tion, addictive properties, and pos-
sible use for suicide. Meprobamate 
( 400 to 800 mg three times a day) 
is obviously preferable when there 
is any risk of suicide. 
(2) Although acute anxiety at-
tacks usually appear as discrete 
clinical syndromes, the patient is 
relatively unaware of the precipi-
tating events and the dynamics. He 
displays overt apprehension and 
the symptoms of autonomic ner-
vous system imbalance. He com-
plains of severe dread, a fear that 
he is dying, or that he is affiicted 
by a terrifying condition. The 
physical symptoms include head-
ache, an inability to concentrate, 
rapid heartbeat, shortness of 
breath, gastrointestinal distress, bi-
zarre sensations, and generalized 
motor hyperactivity. Also, he may 
be hyperventilating, complaining of 
tingling of the extremities and 
sharp twitches of pain in the chest, 
and showing signs such as pallor, 
profuse sweating, and muscle 
spasms. 
Clarification of the patient's 
physical status usually terminates 
the acute attack, but seldom pre-
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vents its recurrence. When these 
patients are first seen the physician 
should explore possible causes in-
cisively. If the anxious condition 
becomes chronic, the patient fo-
cuses on his symptoms so com-
pletely that his awareness of other 
stresses diminishes and valuable in-
formation cannot be obtained. Be-
cause these patients are suffering 
and frightened, they accept direct 
questioning about the quality of 
their interpersonal relationships, 
stresses at home and work, sexual 
activities, basic fears regarding 
adequacy, etc. Psychotherapy is es-
sential because the patient is un-
aware of the dynamics and usually 
of the precipitating events. 
Intravenous sodium amytal (200 
to 500 mg) quickly relieves the 
acute attack. Meprobamate ( 400 to 
800 mg three times a day) or 
chlordiazepoxide (Librium) (10 
to 25 mg three times a day) al-
leviates the anxious condition but 
does not protect the patient from 
recurrence. Therefore, we recom-
mend both intensive psychotherapy 
and medications. Side effects of 
the antianxiety agents (meproba-
mate and chlordiazepoxide) in-
clude withdrawal reactions, para-
doxical reactions, and allergic con-
ditions. 
(3) Chronic anxiety states are 
persistent, the causes obscure, and 
the manifestations multifarious. 
Engel (1962) says: "The somatic 
symptomatology and the physio-
logic changes associated with an-
xiety set in motion a vicious cycle 
-the patient begins to fear the 
onset of the next acute anxiety at-
tack and his perception of somatic 
symptoms reinforces this signal of 
danger." Repeated acute attacks 
thus lead to the chronic condition; 
the baseline level of anxiety be-
tween attacks is raised. 
Chronic anxiety is evidenced by 
the patient's worried, tense ap-
pearance which is accentuated as 
the day goes on and the stresses 
and strains of activity take their 
toll. Although the anxious patient 
has difficulty going to sleep, he 
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feels better in the morning. In con-
trast, the depressed patient is gen-
erally more apathetic in the morn-
ing and brighter in the evening. 
Morbidly anxious patients are pre-
occupied with their mental and 
physical status, speaking freely of 
their symptoms, and betraying 
their agitation by trembling and 
tension. Although they describe 
symptoms easily, they do not know 
what is happening to them. If un-
checked, the condition becomes 
progressively more severe and 
panic states develop. 
Psychiatric referral is recom-
mended. Because the condition is 
both severe and chronic, medica-
tions are usually needed to help 
the patient work with a psychia-
trist. If the patient displays muscle 
tension and agitation and if his 
ego strength is reasonably good, 
meprobamate is preferred. For the 
patient who appears more psychi-
atrically ill, obsessive, and has dif-
fuse complaints, chlordiazepoxide 
(Librium) is usually more effec-
tive. For the even more clinically 
ill patient who will require medi-
cation over a period of months, 
phenothiazine compounds should 
be used. We start with 25 mg of 
chlorpromazine (Thorazine) or 
thioridazine (Mellaril) four times 
a day, check for hypotensive reac-
tions, and then increase the dos-
age by 50 to 100 mg every few 
days until the patient notices some 
relief or side effects apear. The 
most common side effects are dy-
skinesias, particularly parkinson-
ism and akathisia. Dystonia is seen 
only occasionally. In recent years 
the reports of jaundice and agranu-
locytosis have diminshed greatly. 
Hyperpigmentation and photosens-
itivity as well as pigmentation of 
the cornea and lens have been re-
ported (Redlich and Freedman, 
1966). Recently Hollister ( 1966) 
noted that some patients taking 
chlorpromazine for many years 
were found at post-mortem exami-
nation to have coronary artery 
changes, but this has not yet been 
confirmed. 
( 4) Anxiety is also evidenced 
clinically by neurotic behavior and 
attitudes, and a host of charactero-
logic defenses, particularly by pa-
tients who have little awareness of 
their anxiety. Interpersonal rela-
tionships suffer. These manifesta-
tions of anxiety appear so intangi-
ble that the physician is reluctant 
to refer the patient for psychiatric 
consultation until more obvious 
difficulties appear. The neurotic 
behavior includes emotional !abil-
ity, erratic and inconsistent atti-
tudes, and impaired communication 
--especially between patient and 
physician. This may be so great 
that the physician and his patient 
are unable to agree about the 
severity of the illness or the neces-
sity for particular types of treat-
ment. 
We found that highly anxious 
medical patients hold distorted 
views of the severity of their ill-
nesses, maintain negative feelings 
(even flagrant dislike) for hospital-
ization, and distrust their physi-
cians. They display manifold char-
acterologic defenses: irritability, 
suspicion, lack of cooperation, and 
passive-aggressive activities 
(Schwab et al., 1966a). 
When anxiety is expressed 
through these defenses, the severity 
is variable; the defenses become an 
integral part of the character struc-
ture so that the person lives with 
the reputation of being trouble-
some. But more severe anxiety 
states develop when he is stressed 
by medical illness or one of life's 
catastrophes. 
In these patients medications 
have little value; the defenses bind 
the anxiety, and the patients con-
sider their personality symptoms to 
be ego-syntonic. Psychotherapy also 
has limited effectiveness until the 
patient's interpersonal difficulties 
multiply. 
(5) Overwhelming anxiety is a 
conspicuous symptom of schizo-
phrenic reactions, particularly the 
acute undifferentiated type. These 
patients show many of the classic 
signs of schizophrenia: they are 
vague, their thinking is autistic and 
highly personalized, ambivalence 
and indecisiveness are obvious, 
their affect is one of fright and 
suspicion, and of course they may 
be hallucinatory or delusional. 
They are not aware of the sources 
of their anxiety, or their descrip-
tion is so incoherent that they can-
not communicate with others. In 
the milder forms, misdiagnosis is 
common. For example, Lynn 
(1964) fol.ind that of 133 patients 
referred for psychiatric consulta-
tions to the Indiana University 
Medical Center, 34 schizophrenic 
patients had been either misdiag-
nosed or inadequately treated. 
The schizophrenic patients with 
less severe disorders respond well 
to psychotherapy that emphasizes 
specificity, concreteness, and cur-
rent realities. Phenothiazines are 
the only medications which are 
really beneficial. Ambulatory schiz-
ophrenic patients require 200 to 
500 mg of chlorpromazine (Thora-
zine) per day for many months. 
When the medication is discon-
tinued it should be reduced grad-
ually over a period of months. 
(6) Newer concepts of mental 
illness now recognize admixtures of 
anxiety and depression. Once they 
were rigidly differentiated as en-
tities, but now we know a patient 
may appear at any point on the 
continuum ranging from so-called 
"pure" anxiety, through complex 
reactions which manifest both anx-
ious and depressive elements con-
currently, to the more classical, ob-
vious, retarded depressive state. 
Many of these patients respond 
to the newer antidepressant medi-
cations, particularly those which 
exert some phenothiazine-like ac-
tion. Amitriptyline (Elavil) (10 to 
25 mg three or four times a day) 
or nortriptyline hydrochloride 
(Aventyl) (20 to 100 mg daily) 
are recommended. Several British 
investigators (Sargant, 1962; Sar-
gant and Dally, 1962) have re-
ported on the successful use of 
MAO inhibitors for the treatment 
of patients showing anxiety as a 
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prominent feature of their illness; 
however, we have had no expe-
rience with them in the treatment 
of these patients. These various anti-
depressants should not be used in 
combination and can be used in 
tandem only if there is a 7 to 14 
day drug-free interval between 
them. 
It is impossible to generalize 
about psychotherapy for these pa-
tients. Some are benefited; many 
are not. Each case must be indi-
vidualized. 
Conclusions About Drug 
Therapy 
Evaluating the tranquilizing 
agents is complicated for a number 
of reasons; the literature is filled 
with inconsistencies. 
First, the end result is often a 
non-specific, "feeling better," which 
defies quantification. 
Second, selected patient samples 
are used for much of the research. 
In this respect, Rickels (1964) 
found that conscious and uncon-
scious attitudes toward physicians 
differ greatly in lower social class 
patients visiting a medical clinic, 
as compared with middle social 
class patients visiting a psychiatric 
clinic. Moreover, the physician, us-
ually a member of the middle or 
upper social class, is better able 
to understand and treat patients 
with similar backgrounds and aspi-
rations than patients from the lower 
social classes. Yet, this latter group 
is frequently in even greater need 
of help. 
Third, drug response varies with 
the motivation of the subject (Di-
Mascio and Klerman, 1960). Fi-
nancial remuneration, counterpho-
bic defenses, and wishes to 
establish contact with psychiatric 
personnel motivate subjects who 
take part in drug studies. 
Finally, most clinical trials are 
conducted for only four to six 
weeks. We have found that many 
anxious patients will improve on 
any medication during the first few 
weeks. Yet many reports of the ef-
ficacy of these medications are de-
rived from such brief studies. 
Notwithstanding these difficult-
ies, when properly used, the psycho-
pharmacologic agents have bene-
fited many patients. And, just as 
importantly, the use of our rela-
tively crude compounds of the 
1960's lends hope that we are just 
on the threshold of a biochemical 
and psychopharmacologic era in 
which our knowledge of the physi-
ology of the brain will become ex-
act, the mechanics underlying 
mental illness will be revealed, and 
definitive drugs for treatment will 
be found. 
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